查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1610210

PARP 抑制剂药物治疗市场：按药物、适应症、分销管道划分 - 全球预测 2025-2030 年

PARP Inhibitors Drug Therapy Market by Drug (Niraparib, Olaparib, Rucaparib), Indication (Breast Cancer, Ovarian Cancer, Pancreatic Cancer), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年PARP抑制剂药物治疗市值为67.3亿美元，预计2024年将达73.2亿美元，复合年增长率为9.15%，2030年将达到124.3亿美元，预计将达到1000万美元。

PARP抑制剂是标靶癌症治疗中一类关键的药物，主要用于治疗具有特定遗传背景的癌症，例如BRCA突变乳癌和卵巢癌。这些抑制剂主要抑制一种名为聚 ADP-核糖聚合酵素，该酶对于癌细胞 DNA 修復和诱导细胞死亡非常重要。 PARP 抑制剂的需求快速增长是因为它们具有精确的标靶化能力，对健康细胞的附带损害最小，并且对遗传易感肿瘤具有强大的治疗作用。 PARP抑制剂的用途不仅扩展到妇科癌症，也扩展到前列腺癌、胰臟癌、肺癌等，PARP抑制剂的最终用途正在扩大。促进市场成长的关键因素包括基因检测意识的提高和采用、个人化医疗的进步以及临床试验中强大的 PARP 抑制剂产品线。此外，癌症盛行率的不断上升以及对有效治疗方法的迫切需求也是强烈的刺激。然而，该市场受到治疗成本高、药物开发进度复杂、抗药性机制出现等限制因素的困扰，为成长带来了重大挑战。治疗机会在于研究联合治疗、优化治疗持续时间以及探索新的生物标记以提高反应的可预测性。生物技术公司和学术机构之间的合作对于推动突破至关重要。市场动态显示出一个整合阶段，策略收购和联盟可能会增加。创新的重点领域包括开发新型药物传输机制以提高药物生物有效性以及寻找下一代抑制剂以克服抗药性。了解这些市场的细微差别并使策略性倡议与新兴趋势保持一致可以为公司带来竞争优势。 PARP 抑制剂市场的特点是快速创新和激烈竞争，需要灵活的策略来应对监管环境并利用科学进步。

主要市场统计
基准年[2023] 67.3亿美元
预计年份 [2024] 73.2亿美元
预测年份 [2030] 124.3亿美元
复合年增长率（%） 9.15%

市场动态：快速发展的 PARP 抑制剂药物治疗市场的关键市场洞察

PARP 抑制剂药物治疗市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 癌症盛行率增加
    • 全球临床试验数量增加
    • 政府增加对 PARP 药物的核准
  • 市场限制因素
    • 治疗费用上涨
  • 市场机会
    • 正在进行的研究和开发计划，以引入新的药物疗法
    • 加强癌症治疗的政府计划
  • 市场挑战
    • 对药物治疗副作用的担忧

波特五力：驾驭 PARP 抑制剂药物治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 PARP 抑制剂药物治疗市场的外部影响

外部宏观环境因素在塑造 PARP 抑制剂药物治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解 PARP 抑制剂药物治疗市场的竞争状况

对 PARP 抑制剂药物治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV定位矩阵PARP抑制剂药物治疗市场供应商绩效评估

FPNV定位矩阵是评估PARP抑制剂药物治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了 PARP 抑制剂药物治疗市场的成功之路

PARP 抑制剂药物治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症发生率增加
      • 世界各地的临床试验不断增加
      • 政府增加对 PARP 药物的核准
    • 抑制因素
      • 治疗费用高
    • 机会
      • 正在进行的研究和开发计划，以引入新的药物疗法
      • 加强癌症治疗的政府计划
    • 任务
      • 对药物治疗副作用的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 PARP 抑制剂药物治疗市场（依药物划分）

  • 尼拉帕尼
  • 奥拉帕尼
  • 卢卡帕尼
  • 他拉佐帕尼

第七章 PARP 抑制剂药物治疗市场（按适应症）

  • 乳癌
  • 卵巢癌
  • 胰臟癌
  • 摄护腺癌

第八章 PARP 抑制剂药物治疗市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章 美洲PARP抑制剂药物治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太PARP抑制剂药物治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章：欧洲、中东和非洲的PARP抑制剂药物治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Artios Pharma Limited
  • AstraZeneca PLC
  • BeiGene, Inc.
  • Bristol-Myers Squibb Company
  • Clovis Oncology
  • GlaxoSmithKline PLC
  • IMPACT Therapeutics
  • Jeil Pharmaceuticals Co. Ltd.
  • Jiangsu Hengrui Pharmaceuticals Company Ltd.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics
  • Merck & Co., Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Repare Therapeutics, Inc.
Product Code: MRR-AD517FAA716F

The PARP Inhibitors Drug Therapy Market was valued at USD 6.73 billion in 2023, expected to reach USD 7.32 billion in 2024, and is projected to grow at a CAGR of 9.15%, to USD 12.43 billion by 2030.

PARP inhibitors are a class of drugs pivotal to targeted cancer therapy, fundamentally employed in treating cancers with specific genetic contexts, such as BRCA-mutated breast and ovarian cancers. These inhibitors focus on blocking the enzyme poly ADP-ribose polymerase, crucial for DNA repair in cancer cells, thus inducing cell death. The burgeoning necessity for PARP inhibitors stems from their precision-targeting capability, which minimizes collateral damage to healthy cells and delivers a potent therapeutic effect in genetically susceptible tumors. Their application is extending beyond gynecological cancers to potentially include prostate, pancreatic, and lung cancers, broadening their end-use scope. Key market growth influencers include increased awareness and adoption of genetic testing, developments in personalized medicine, and a robust pipeline of PARP inhibitors under clinical trials. Additionally, the growing prevalence of cancer and the urgent demand for effective therapies serve as strong stimuli. However, the market grapples with limitations such as high treatment costs, complex drug development timelines, and the emergence of resistance mechanisms, which are substantial challenges to growth. Opportunities lie in advancing research for combination therapies, optimizing treatment durations, and exploring novel biomarkers to enhance response predictability. The interplay of collaborations between biotech firms and academic institutions can be pivotal in driving breakthroughs. Market dynamics suggest a consolidation phase with a potential upswing in strategic acquisitions and partnerships. Focus areas for innovation include formulating novel delivery mechanisms to improve drug bioavailability and exploring next-generation inhibitors overcoming resistance. Understanding these market nuances and aligning strategic initiatives with emerging trends can offer firms a competitive advantage. The nature of the PARP inhibitors market, characterized by rapid innovation and high competition, necessitates agile strategies to maneuver through regulatory landscapes and capitalize on scientific advancements.

KEY MARKET STATISTICS
Base Year [2023] USD 6.73 billion
Estimated Year [2024] USD 7.32 billion
Forecast Year [2030] USD 12.43 billion
CAGR (%) 9.15%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving PARP Inhibitors Drug Therapy Market

The PARP Inhibitors Drug Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancers
    • Growing numbers of clinical trials worldwide
    • Elevation in government approvals for PARP drugs
  • Market Restraints
    • High cost of treatment
  • Market Opportunities
    • Ongoing research and development projects to introduce novel drug therapies
    • Governmental programs to enhance the cancer treatment therapies
  • Market Challenges
    • Concerns associated with side effects of drug therapy

Porter's Five Forces: A Strategic Tool for Navigating the PARP Inhibitors Drug Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the PARP Inhibitors Drug Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the PARP Inhibitors Drug Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the PARP Inhibitors Drug Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the PARP Inhibitors Drug Therapy Market

A detailed market share analysis in the PARP Inhibitors Drug Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the PARP Inhibitors Drug Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the PARP Inhibitors Drug Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the PARP Inhibitors Drug Therapy Market

A strategic analysis of the PARP Inhibitors Drug Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the PARP Inhibitors Drug Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Artios Pharma Limited, AstraZeneca PLC, BeiGene, Inc., Bristol-Myers Squibb Company, Clovis Oncology, GlaxoSmithKline PLC, IMPACT Therapeutics, Jeil Pharmaceuticals Co. Ltd., Jiangsu Hengrui Pharmaceuticals Company Ltd., Johnson & Johnson Services, Inc., Karyopharm Therapeutics, Merck & Co., Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., and Repare Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the PARP Inhibitors Drug Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Niraparib, Olaparib, Rucaparib, and Talazoparib.
  • Based on Indication, market is studied across Breast Cancer, Ovarian Cancer, Pancreatic Cancer, and Prostate Cancer.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancers
      • 5.1.1.2. Growing numbers of clinical trials worldwide
      • 5.1.1.3. Elevation in government approvals for PARP drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development projects to introduce novel drug therapies
      • 5.1.3.2. Governmental programs to enhance the cancer treatment therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with side effects of drug therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. PARP Inhibitors Drug Therapy Market, by Drug

  • 6.1. Introduction
  • 6.2. Niraparib
  • 6.3. Olaparib
  • 6.4. Rucaparib
  • 6.5. Talazoparib

7. PARP Inhibitors Drug Therapy Market, by Indication

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Ovarian Cancer
  • 7.4. Pancreatic Cancer
  • 7.5. Prostate Cancer

8. PARP Inhibitors Drug Therapy Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas PARP Inhibitors Drug Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific PARP Inhibitors Drug Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa PARP Inhibitors Drug Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Artios Pharma Limited
  • 3. AstraZeneca PLC
  • 4. BeiGene, Inc.
  • 5. Bristol-Myers Squibb Company
  • 6. Clovis Oncology
  • 7. GlaxoSmithKline PLC
  • 8. IMPACT Therapeutics
  • 9. Jeil Pharmaceuticals Co. Ltd.
  • 10. Jiangsu Hengrui Pharmaceuticals Company Ltd.
  • 11. Johnson & Johnson Services, Inc.
  • 12. Karyopharm Therapeutics
  • 13. Merck & Co., Inc.
  • 14. Ono Pharmaceutical Co., Ltd.
  • 15. Pfizer Inc.
  • 16. Repare Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. PARP INHIBITORS DRUG THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PARP INHIBITORS DRUG THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PARP INHIBITORS DRUG THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2023